Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 5/20 | 0.47 |
| ▸ | PPARD | Q03181 | 5/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22649521 | 1.00 | KCNT1 (0.57) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL29463491 | 1.00 | KCNT1 (0.57) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL29463464 | 1.00 | KCNT1 (0.57) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL22649477 | 0.89 | PPARD (0.49) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL29463495 | 0.89 | PPARD (0.49) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL24660179 | 0.88 | KMT2A (0.49) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL22649547 | 0.88 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22637889 | 0.88 | KMT2A (0.49) | KCNT1TP53SMN1; SMN2TDP1ACACB | |
| SCHEMBL22649224 | 0.88 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA | |
| SCHEMBL22637858 | 0.88 | KCNT1 (0.60) | KCNT1TDP1ACACBPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNT1 1/4885TP53 4492/4885SMN1; SMN2 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.